SRRA · Sierra Oncology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $67.15M | $45.12M | $53.25M | $41.08M | $30.16M | $33.90M |
| SG&A | $27.43M | $20.12M | $13.74M | $14.34M | $12.46M | $14.18M |
| Total Operating Expenses | $94.58M | $65.24M | $66.99M | $55.42M | $42.62M | $48.08M |
| D&A | $305.0K | $238.0K | $83.0K | $111.0K | $258.0K | $197.0K |
| Operating Income | ($94.58M) | ($64.94M) | ($66.99M) | ($55.42M) | ($42.62M) | ($48.08M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($3.0K) | $142.0K | ($160.0K) | ($302.0K) | $156.0K | $143.0K |
| Net Income | ($94.66M) | ($80.90M) | ($88.28M) | ($53.34M) | ($42.02M) | ($47.87M) |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $104.75M | $104.06M | $147.53M | $106.05M | $100.35M | $109.01M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.16M | $2.21M | $1.02M | $1.29M | $1.34M | $2.60M |
| Current Assets | $107.39M | $106.47M | $149.90M | $108.75M | $101.72M | $110.35M |
| Total Assets | $109.37M | $107.49M | $151.33M | $109.47M | $102.20M | $110.97M |
| Current Liabilities | $12.88M | $9.35M | $64.61M | $10.10M | $7.47M | $7.72M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $13.37M | $9.53M | $64.98M | $14.99M | $7.47M | $7.72M |
| Stockholders' Equity | $96.00M | $97.96M | $86.34M | $94.48M | $94.73M | $103.25M |
| Retained Earnings | ($941.25M) | ($846.59M) | ($765.69M) | ($677.41M) | ($624.08M) | ($582.05M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($78.96M) | ($52.37M) | ($51.18M) | ($41.16M) | ($36.16M) | ($41.16M) |
| Investing Cash Flow | ($72.0K) | ($12.0K) | ($39.0K) | ($171.0K) | ($80.0K) | ($146.0K) |
| Financing Cash Flow | $79.81M | $8.90M | $92.74M | $196.0K | $27.59M | $196.0K |
| CapEx | $72.0K | $12.0K | $39.0K | $118.0K | $93.0K | $214.0K |
| Free Cash Flow | ($79.04M) | ($52.38M) | ($51.22M) | ($41.28M) | ($36.26M) | ($41.38M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.83 | 0.65 | 0.58 | 0.77 | 0.86 | 0.86 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -86.6% | -75.3% | -58.3% | -48.7% | -41.1% | -43.1% |
| Return on equity | -98.6% | -82.6% | -102.2% | -56.5% | -44.4% | -46.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 8.34 | 11.38 | 2.32 | 10.77 | 13.61 | 14.28 |
| Quick ratio | 8.34 | 11.38 | 2.32 | 10.77 | 13.61 | 14.28 |
| Cash ratio | 8.13 | 11.13 | 2.28 | 10.50 | 13.43 | 14.11 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.14 | 1.10 | 1.75 | 1.16 | 1.08 | 1.07 |
| Liabilities / Assets | 0.12 | 0.09 | 0.43 | 0.14 | 0.07 | 0.07 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -45.6% | 3.1% | -20.9% | -30.0% | 11.3% | -1100.4% |
| Net income growth (YoY) | -17.0% | 8.4% | -65.5% | -26.9% | 12.2% | -600.6% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -50.9% | -2.3% | -24.1% | -13.9% | 12.4% | -1057.7% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -2.0% | 13.5% | -8.6% | -0.3% | -8.3% | - |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sierra Oncology against the 5 most active filers in the same SIC group.